## Florian M E Wagenlehner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3788558/publications.pdf

Version: 2024-02-01

175 papers 6,246 citations

66343 42 h-index 70 g-index

196 all docs

196 docs citations

196 times ranked 5728 citing authors

#	Article	IF	Citations
1	Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet, The, 2015, 385, 1949-1956.	13.7	318
2	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clinical Infectious Diseases, 2016, 63, 754-762.	5.8	281
3	Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study. European Urology, 2013, 63, 521-527.	1.9	280
4	Global epidemiology of urinary tract infections. Current Opinion in Infectious Diseases, 2016, 29, 73-79.	3.1	250
5	Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. European Urology, 2016, 69, 286-297.	1.9	195
6	Once-Daily Plazomicin for Complicated Urinary Tract Infections. New England Journal of Medicine, 2019, 380, 729-740.	27.0	159
7	Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. International Journal of Antimicrobial Agents, 2011, 38, 64-70.	2.5	158
8	A Pollen Extract (Cernilton) in Patients with Inflammatory Chronic Prostatitis–Chronic Pelvic Pain Syndrome: A Multicentre, Randomised, Prospective, Double-Blind, Placebo-Controlled Phase 3 Study. European Urology, 2009, 56, 544-551.	1.9	146
9	Epidemiology, definition and treatment of complicated urinary tract infections. Nature Reviews Urology, 2020, 17, 586-600.	3.8	132
10	Update on biofilm infections in the urinary tract. World Journal of Urology, 2012, 30, 51-57.	2.2	128
11	Urogenital Infection as a Risk Factor for Male Infertility. Deutsches Ärzteblatt International, 2017, 114, 339-346.	0.9	122
12	National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. European Urology, 2013, 63, 953-959.	1.9	108
13	Use of the UPOINT Chronic Prostatitis/Chronic Pelvic Pain Syndrome Classification in European Patient Cohorts: Sexual Function Domain Improves Correlations. Journal of Urology, 2010, 184, 2339-2345.	0.4	105
14	Acute Epididymitis Revisited: Impact of Molecular Diagnostics on Etiology and Contemporary Guideline Recommendations. European Urology, 2015, 68, 428-435.	1.9	97
15	Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 107-117.	1.4	96
16	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology, 2017, 104, 11-21.	1.0	92
17	Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. European Urology, 2017, 72, 865-868.	1.9	89
18	Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 224-230.	0.4	85

#	Article	IF	CITATIONS
19	Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urologia Internationalis, 2018, 101, 327-336.	1.3	81
20	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urologia Internationalis, 2018, 100, 271-278.	1.3	80
21	Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 653-663.	0.4	79
22	Uncomplicated Urinary Tract Infections. Deutsches A& #x0308; rzteblatt International, 2011, 108, 415-23.	0.9	77
23	Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010. World Journal of Urology, 2014, 32, 1587-1594.	2.2	77
24	The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Deutsches Ärzteblatt International, 2016, 113, 11-22.	0.9	73
25	Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World Journal of Urology, 2014, 32, 791-801.	2.2	71
26	Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. World Journal of Urology, 2016, 34, 1193-1200.	2.2	70
27	The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU International, 2007, 100, 733-737.	2.5	69
28	Treatment Options for Carbapenem-Resistant Gram-Negative Infections. Deutsches Ärzteblatt International, 2018, 115, 345-352.	0.9	68
29	"TREXIT 2020― why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer and Prostatic Diseases, 2020, 23, 62-65.	3.9	68
30	Antibiotic Prophylaxis in Urology Departments, 2005–2010. European Urology, 2013, 63, 386-394.	1.9	65
31	The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens, 2016, 5, 10.	2.8	62
32	An update on uncomplicated urinary tract infections in women. Current Opinion in Urology, 2009, 19, 368-374.	1.8	61
33	The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: PartÂ1. Urologia Internationalis, 2018, 100, 263-270.	1.3	58
34	Reducing infection rates after prostate biopsy. Nature Reviews Urology, 2014, 11, 80-86.	3.8	55
35	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clinical Microbiology and Infection, 2021, 27, 671-686.	6.0	54
36	Antimicrobials in urogenital infections. International Journal of Antimicrobial Agents, 2011, 38, 3-10.	2.5	50

#	Article	IF	Citations
37	Urinary tract infections and bacterial prostatitis in men. Current Opinion in Infectious Diseases, 2014, 27, 97-101.	3.1	50
38	New Self-Reporting Questionnaire to Assess Urinary Tract Infections and Differential Diagnosis: Acute Cystitis Symptom Score. Urologia Internationalis, 2014, 92, 230-236.	1.3	49
39	Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Experimental and Therapeutic Medicine, 2015, 9, 658-666.	1.8	49
40	Management of Urosepsis in 2018. European Urology Focus, 2019, 5, 5-9.	3.1	49
41	Urinary Concentrations and Antibacterial Activities of Nitroxoline at 250 Milligrams versus Trimethoprim at 200 Milligrams against Uropathogens in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2014, 58, 713-721.	3.2	47
42	An update on classification and management of urosepsis. Current Opinion in Urology, 2017, 27, 133-137.	1.8	47
43	Are Antisperm Antibodies Really Associated with Proven Chronic Inflammatory and Infectious Diseases of the Male Reproductive Tract?. European Urology, 2009, 56, 708-715.	1.9	46
44	Bacterial prostatitis. World Journal of Urology, 2013, 31, 711-716.	2.2	45
45	Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	44
46	Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Urology, 2017, 103, 191-197.	1.0	43
47	Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World Journal of Urology, 2020, 38, 17-26.	2.2	43
48	Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. European Urology, 2019, 76, 273-275.	1.9	42
49	European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. European Urology, 2021, 79, 11-15.	1.9	41
50	Hospital-acquired urinary tract infections. Journal of Hospital Infection, 2000, 46, 171-181.	2.9	38
51	TET enzymes are successively expressed during human spermatogenesis and their expression level is pivotal for male fertility. Human Reproduction, 2016, 31, 1411-1424.	0.9	38
52	Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World Journal of Urology, 2018, 36, 323-330.	2.2	38
53	Pharmacokinetic Characteristics of Antimicrobials and Optimal Treatment of Urosepsis. Clinical Pharmacokinetics, 2007, 46, 291-305.	3.5	37
54	Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis. Antimicrobial Agents and Chemotherapy, 2009, 53, 1567-1573.	3.2	35

#	Article	IF	Citations
55	Asymptomatic Bacteriuria in Elderly Patients. Drugs and Aging, 2005, 22, 801-807.	2.7	34
56	Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opinion on Pharmacotherapy, 2007, 8, 1667-1674.	1.8	34
57	Update on Strategies to Reduce Infectious Complications After Prostate Biopsy. European Urology Focus, 2019, 5, 20-28.	3.1	33
58	Acute epididymitis induces alterations in sperm protein composition. Fertility and Sterility, 2014, 101, 1609-1617.e5.	1.0	31
59	Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant. European Urology Focus, 2016, 2, 394-399.	3.1	31
60	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clinical Genitourinary Cancer, 2017, 15, 356-362.	1.9	31
61	Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. Journal of Medical Microbiology, 2017, 66, 788-797.	1.8	30
62	Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). Journal of Infection and Chemotherapy, 2018, 24, 278-283.	1.7	29
63	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. Urologia Internationalis, 2018, 101, 16-24.	1.3	28
64	Is Preoperative Assessment and Treatment of Asymptomatic Bacteriuria Necessary for Reducing the Risk of Postoperative Symptomatic Urinary Tract Infections After Urologic Surgical Procedures?. Urology, 2017, 99, 100-105.	1.0	26
65	Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults. Deutsches Ärzteblatt International, 2017, 114, 866-873.	0.9	26
66	Development and validation of a nomogram predicting recurrence risk in women with symptomatic urinary tract infection. International Journal of Urology, 2014, 21, 929-934.	1.0	25
67	Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Experimental and Therapeutic Medicine, 2014, 8, 1032-1038.	1.8	25
68	The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment. Urologia Internationalis, 2016, 97, 402-409.	1.3	25
69	Modern diagnostic methods for urinary tract infections. Expert Review of Anti-Infective Therapy, 2016, 14, 1047-1063.	4.4	25
70	Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. International Urology and Nephrology, 2017, 49, 1311-1318.	1.4	24
71	A Randomized, Double-Blind, Parallel-Group, Multicenter Clinical Study of <b><i>Escherichia coli</i></b> -Lyophilized Lysate for the Prophylaxis of Recurrent Uncomplicated Urinary Tract Infections. Urologia Internationalis, 2015, 95, 167-176.	1.3	23
72	Is overactive bladder in the female surgically curable by ligament repair?. Central European Journal of Urology, 2017, 70, 53-59.	0.3	23

#	Article	IF	Citations
73	Monocyte-derived extracellular trap (MET) formation induces aggregation and affects motility of human spermatozoa in vitro. Systems Biology in Reproductive Medicine, 2019, 65, 357-366.	2.1	21
74	Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis. Urologia Internationalis, 2019, 102, 83-95.	1.3	21
<b>7</b> 5	Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli. International Journal of Antimicrobial Agents, 2018, 52, 783-789.	2,5	20
76	Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study. PLoS ONE, 2019, 14, e0214710.	2.5	20
77	Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women. World Journal of Urology, 2020, 38, 63-72.	2.2	20
78	Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose. Chemotherapy, 2011, 57, 97-107.	1.6	19
79	Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2017, 58, 96-109.	3.3	19
80	Chronic Prostatitis Affects Male Reproductive Health and Is Associated with Systemic and Local Epigenetic Inactivation of C-X-C Motif Chemokine 12 Receptor C-X-C Chemokine Receptor Type 4. Urologia Internationalis, 2017, 98, 89-101.	1.3	18
81	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. Antibiotics, 2018, 7, 6.	3.7	18
82	Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II. World Journal of Urology, 2020, 38, 1977-1988.	2.2	18
83	A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance. Journal of Global Antimicrobial Resistance, 2022, 28, 18-29.	2.2	18
84	Asymptomatic Bacteriuria in Clinical Urological Practice: Preoperative Control of Bacteriuria and Management of Recurrent UTI. Pathogens, 2016, 5, 4.	2.8	17
85	Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw486.	3.0	17
86	Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMRO and its interaction with KLF4. Cell Communication and Signaling, 2017, 15, 40.	6.5	17
87	Acute Cystitis Symptom Score (ACSS): Clinical Validation of the Italian Version. Antibiotics, 2020, 9, 104.	3.7	17
88	Pollen Extract for Chronic Prostatitisâ€"Chronic Pelvic Pain Syndrome. Urologic Clinics of North America, 2011, 38, 285-292.	1.8	16
89	Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics, 2021, 10, 685.	3.7	16
90	Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study. World Journal of Urology, 2014, 32, 1595-1603.	2.2	15

#	Article	IF	Citations
91	Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment. Antibiotics, 2018, 7, 43.	3.7	15
92	High prevalence of urogenital infection/inflammation in patients with azoospermia does not impede surgical sperm retrieval. Andrologia, 2019, 51, e13401.	2.1	15
93	The negative aftermath of prostate biopsy: prophylaxis, complications and antimicrobial stewardship: results of the global prevalence study of infections in urology 2010–2019. World Journal of Urology, 2021, 39, 3423-3432.	2.2	15
94	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infectious Diseases and Therapy, 2021, 10, 2399-2414.	4.0	15
95	Management of uncomplicated recurrent urinary tract infections. BJU International, 2022, 129, 668-678.	2.5	15
96	The Global Prevalence of Infections in Urology (GPUI) Study: A Worldwide Surveillance Study in Urology Patients. European Urology Focus, 2016, 2, 345-347.	3.1	14
97	Urogenital infections. World Journal of Urology, 2020, 38, 1-2.	2.2	14
98	Increase of leucocyte-derived extracellular traps (ETs) in semen samples from human acute epididymitis patients—a pilot study. Journal of Assisted Reproduction and Genetics, 2020, 37, 2223-2231.	2.5	14
99	Hyperbaric Oxygenation in the Treatment of Fournier's Gangrene: A Systematic Review. Urologia Internationalis, 2021, 105, 247-256.	1.3	14
100	Emerging drugs for bacterial urinary tract infections. Expert Opinion on Emerging Drugs, 2010, 15, 375-397.	2.4	13
101	Determination of leucocyte extracellular traps (ETs) in seminal fluid (ex vivo ) in infertile patients—A pilot study. Andrologia, 2019, 51, e13356.	2.1	13
102	Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. International Journal of Antimicrobial Agents, 2019, 54, 633-641.	2.5	13
103	Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments?. European Urology Focus, 2019, 5, 29-35.	3.1	13
104	In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default?. European Urology, 2019, 75, 205-207.	1.9	13
105	Metagenomics in diagnosis and improved targeted treatment of UTI. World Journal of Urology, 2020, 38, 35-43.	2.2	13
106	The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version. Central European Journal of Urology, 2018, 71, 134-141.	0.3	11
107	Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1558-1566.	6.0	11
108	Grey Zones in the Field of Urinary Tract Infections. European Urology Focus, 2016, 2, 460-462.	3.1	10

#	Article	IF	CITATIONS
109	Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2016, 60, 3309-3315.	3.2	10
110	Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli. International Journal of Antimicrobial Agents, 2019, 54, 55-61.	2.5	10
111	Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study. World Journal of Urology, 2020, 38, 27-34.	2.2	10
112	Validation of the American English Acute Cystitis Symptom Score. Antibiotics, 2020, 9, 929.	3.7	10
113	Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria. Urologia Internationalis, 2021, 105, 278-284.	1.3	10
114	Elevated seminal plasma estradiol and epigenetic inactivation of ESR1 and ESR2 is associated with CP/CPPS. Oncotarget, 2018, 9, 19623-19639.	1.8	10
115	Psychosocial burden of recurrent uncomplicated urinary tract infections GMS Infectious Diseases, 2022, 10, Doc01.	0.8	10
116	How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clinical Phytoscience, 2017, $3$ , .	1.6	9
117	Novel Antibiotics in the Treatment of Urinary Tract Infections. European Urology Focus, 2019, 5, 10-12.	3.1	9
118	Cefiderocol for treatment of complicated urinary tract infections. Lancet Infectious Diseases, The, 2019, 19, 22-23.	9.1	9
119	Anti-Bacterial Effects of Essential Oils against Uropathogenic Bacteria. Antibiotics, 2020, 9, 358.	3.7	9
120	Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVIDâ€19) pandemic: an international accelerated consensus statement. BJU International, 2021, 127, 729-741.	2.5	9
121	Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 197.e9-197.e17.	1.6	9
122	Chronic Prostatitis/Chronic Pelvic Pain Syndrome Leads to Impaired Semen Parameters, Increased Sperm DNA Fragmentation and Unfavorable Changes of Sperm Protamine mRNA Ratio. International Journal of Molecular Sciences, 2021, 22, 7854.	4.1	9
123	Treatment of Asymptomatic Bacteriuria Might Be Harmful. Clinical Infectious Diseases, 2015, 61, civ698.	5.8	8
124	Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infectionsâ€"Preliminary Considerations and Conclusions from a Non-Interventional Study. Antibiotics, 2022, 11, 314.	3.7	8
125	Expression of terminal deoxynucleotidyl transferase (TdT) in classical seminoma: a potential diagnostic pitfall. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 433-440.	2.8	7
126	Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption. International Journal of Antimicrobial Agents, 2018, 51, 422-426.	2.5	7

#	Article	IF	Citations
127	Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy. Investigative and Clinical Urology, 2020, 61, 498.	2.0	7
128	Ceftolozane-tazobactam versus levofloxacin in urinary tract infection – Authors' reply. Lancet, The, 2015, 386, 1242.	13.7	6
129	Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects. FASEB Journal, 2018, 32, 1130-1138.	0.5	6
130	Transurethral Resection of the Prostate: are We Following the Guidelines? - Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study. Journal of Chemotherapy, 2019, 31, 15-22.	1.5	6
131	Natural Bred $\hat{l}\mu$ 2-Phages Have an Improved Host Range and Virulence against Uropathogenic Escherichia coli over Their Ancestor Phages. Antibiotics, 2021, 10, 1337.	3.7	6
132	Re: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. European Urology, 2022, 81, 213.	1.9	6
133	No benefit of α-blockers for chronic prostatitis. Nature Reviews Urology, 2009, 6, 183-184.	3.8	5
134	Urodynamic Impact of Acute Urinary Retention in Patients with Benign Prostatic Hyperplasia: A 2-Year Follow-Up after Transurethral Resection of the Prostate. Urologia Internationalis, 2011, 86, 73-79.	1.3	5
135	Management of the Urologic Sepsis Syndrome. European Urology Supplements, 2016, 15, 102-111.	0.1	5
136	Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 959-966.	3.3	5
137	Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	5
138	Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. Journal of Urology, 2021, 205, 826-832.	0.4	5
139	The efficacy and tolerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome: a 26 weeks, randomized, controlled, single-blinded, phase III study. Minerva Urology and Nephrology, 2023, 74, .	2.5	5
140	Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. European Urology Focus, 2022, 8, 1476-1482.	3.1	5
141	Re: Procalcitonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-analysis. European Urology, 2014, 66, 178.	1.9	4
142	A new way to prevent urinary tract infections?. Lancet Infectious Diseases, The, 2017, 17, 467-468.	9.1	4
143	Ceftazidime–avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections. Future Microbiology, 2017, 12, 655-670.	2.0	4
144	Guidelines in urology: Lights and shadows. Urologia, 2020, 87, 125-129.	0.7	4

#	Article	IF	CITATIONS
145	Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey. Caspian Journal of Internal Medicine, 2019, 10, 132-141.	0.2	4
146	Editorial Comment from <scp>D</scp> r <scp>W</scp> agenlehner to <scp>H</scp> ospital admissions after transrectal ultrasoundâ€guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in <scp>E</scp> ngland. International Journal of Urology, 2015, 22, 186-186.	1.0	3
147	Studying ceftazidime-avibactam in selected populations. Lancet Infectious Diseases, The, 2016, 16, 621-623.	9.1	3
148	Associated measures to antibiotic prophylaxis in urology. World Journal of Urology, 2020, 38, 9-15.	2.2	3
149	Physiological and pharmacological impact of oxytocin on epididymal propulsion during the ejaculatory process in rodents and men. FASEB Journal, 2021, 35, e21639.	0.5	3
150	Clinical Validation of the Greek Version of the Acute Cystitis Symptom Score (ACSS)â€"Part II. Antibiotics, 2021, 10, 1253.	3.7	3
151	The Management of Urinary Tract Infections during the COVID-19 Pandemic: What Do We Need to Know?. Uro, 2022, 2, 55-64.	0.8	3
152	Reply to Dino PapeÅ <sub>i</sub> , Ana JeronÄić's Letter to the Editor re: Giuseppe Magistro, Florian M.E. Wagenlehner, Magnus Grabe, Wolfgang Weidner, Christian G. Stief, J. Curtis Nickel. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 2016;69:286–97. European Urology, 2016, 70, e166-e167.	1.9	2
153	Preventing urinary tract infections in patients with neurogenic bladder. Lancet Infectious Diseases, The, 2018, 18, 926-927.	9.1	2
154	Recent research in urological infections. Nature Reviews Urology, 2020, 17, 65-66.	3.8	2
155	The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer. Urology, 2020, 145, 30-37.	1.0	2
156	Sexual Health in HIV-Positive Men Under Stable Antiretroviral Therapy During a 12-Month Period. Journal of Sexual Medicine, 2021, 18, 284-294.	0.6	2
157	Linguistic and clinical validation of the acute cystitis symptom score in German-speaking Swiss women with acute cystitis. International Urogynecology Journal, 2021, 32, 3275-3286.	1.4	2
158	Comparative Analysis of Guideline Adherence between Germany and Austria by Using the Example of Uncomplicated Urinary Tract Infections. Urologia Internationalis, 2022, 106, 1018-1024.	1.3	2
159	Translation and validation of the Korean version of acute cystitis symptom score. Investigative and Clinical Urology, 2022, 63, 221.	2.0	2
160	Response to â€~Aberrant expression of TdT in seminomatous germ cell neoplasia'. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 387-387.	2.8	1
161	Understanding clinical variables to improve empirical antibiotic therapy for UTI. Nature Reviews Urology, 2019, 16, 695-696.	3.8	1
162	Some thoughts on the effect of non-linearity on innovation in urological surgery. Central European Journal of Urology, 2013, 66, 121-5.	0.3	1

#	Article	IF	CITATIONS
163	Re: COVID-19 Coagulopathy: Considerations for Urologists. Journal of Urology, 2020, 204, 848-849.	0.4	1
164	Comparison of Urine Flow Cytometry on the UF-1000i System and Urine Culture of Urine Samples from Urological Patients. Urologia Internationalis, 2022, 106, 858-868.	1.3	1
165	Reply from Authors re: Riccardo Bartoletti, Tommaso Cai. Prostate Biopsies Should Be Performed According to a Standard of Care. Eur Urol 2013;63:528–9. European Urology, 2013, 63, 529-530.	1.9	O
166	Clinical presentation, risk factors and use of antibiotics in urinary tract infections. Surgery, 2014, 32, 297-303.	0.3	0
167	Antibiotic Resistance and Novel Antibiotics for the Treatment of Urinary Tract Infections. Urogenital Tract Infection, 2016, 11, 43.	0.2	O
168	Re: Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis. Journal of Urology, 2016, 195, 224-225.	0.4	0
169	Editorial Comment. Journal of Urology, 2017, 198, 114-115.	0.4	O
170	Re: Letter to the editor. International Urology and Nephrology, 2018, 50, 875-875.	1.4	0
171	Re: Acute Pyelonephritis in Adults. European Urology, 2018, 74, 676.	1.9	O
172	Epidemiological study of the prevalence of cystitis in women of the Voronezh region. Experimental and $\theta_i$ linical Urology, 2021, 14, 10-18.	0.3	0
173	Reply by Authors. Journal of Urology, 2021, 205, 832-832.	0.4	O
174	Editorial Comment. Journal of Urology, 2020, 203, 577-578.	0.4	0
175	Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract. GMS Infectious Diseases, 2020, 8, Doc12.	0.8	O